Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Bortezomib ocular toxicity refers to eye complications caused by the cancer medication bortezomib, which is commonly used to treat multiple myeloma and certain lymphomas. This drug can sometimes affect the eyes, leading to inflammation, corneal damage, or blurred vision. Most cases are mild and improve after adjusting the dose or stopping treatment. Regular eye monitoring helps detect changes early.
read more about bortezomib ocular toxicity ...Bortezomib works by blocking proteasomes, which are responsible for breaking down damaged proteins in cells. Although effective in killing cancer cells, this process can also disrupt normal cell activity in eye tissues. Toxicity may result from direct effects on the corneal surface or secondary inflammation. Risk increases with cumulative drug exposure or pre-existing eye conditions.
Common symptoms include redness, eye pain, dryness, and blurred vision. Some patients experience excessive tearing, photophobia, or a gritty sensation. In rare cases, corneal ulcers or conjunctivitis may develop. Symptoms often appear within weeks of starting therapy and can vary in intensity from mild irritation to significant discomfort.
Diagnosis usually includes:
Treatment involves discontinuing or adjusting the bortezomib dose under medical supervision. Lubricating eye drops and topical corticosteroids are commonly prescribed to reduce irritation and inflammation. In cases of corneal damage, antibiotic ointments may be added to prevent infection. Most patients recover well with early detection and supportive care.
If you are receiving bortezomib and notice blurry vision, redness, or sensitivity, report it immediately. Some patients develop eye-related side effects that need prompt attention. Early care helps prevent complications and guide adjustments in treatment. Routine monitoring is often recommended during therapy. Quick communication supports safer care.
Bortezomib can trigger inflammation or surface irritation that affects the cornea and conjunctiva. Some people develop dryness, redness, or blurred vision after starting treatment. Effects can range from mild discomfort to more serious corneal problems in rare cases. Early reporting helps clinicians adjust care before symptoms worsen.
New blur, eye pain, strong redness, or light sensitivity should be reported right away. Excess tearing and a gritty sensation can also be signs of surface injury. Symptoms often begin within weeks of therapy but timing can vary. Prompt evaluation helps rule out infection or corneal ulcer.
Management often starts with supportive eye drops like lubricants and, when appropriate, anti-inflammatory drops. The oncology team can adjust dosage or pause treatment if eye effects are significant. Antibiotic ointment might be used if the cornea has surface breakdown. Coordination between oncology and ophthalmology guides safe decisions.
Yes, especially if symptoms appear or if a patient already has dry eye or corneal disease. Baseline and follow-up exams can document changes over time. Quick assessments help prevent complications that could interrupt cancer therapy. Patients should not self-stop medication without medical guidance.
1. Bortezomib Injection (Drug Information). MedlinePlus. https://medlineplus.gov/druginfo/meds/a605019.html. Accessed January 16, 2026.
2. Bortezomib (Clinical Overview). StatPearls, NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/ (search: "Bortezomib StatPearls"). Accessed January 16, 2026.
3. Ocular Adverse Events Reported With Bortezomib (Case Reports/Series). PubMed. https://pubmed.ncbi.nlm.nih.gov/ (search: "bortezomib ocular toxicity"). Accessed January 16, 2026.
4. Bortezomib-Associated Keratopathy (Reports/Reviews). PubMed. https://pubmed.ncbi.nlm.nih.gov/ (search: "bortezomib keratopathy"). Accessed January 16, 2026.
5. Drug-Induced Ocular Side Effects (Background). EyeWiki. https://eyewiki.org. Accessed January 16, 2026.
6. Proteasome Inhibitors and Ocular Effects (Background). PubMed. https://pubmed.ncbi.nlm.nih.gov/ (search: "proteasome inhibitor ocular adverse effects"). Accessed January 16, 2026.